Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Quanterix Corporation
News We’re Watching: MedRhythms App Gets FDA Clearance, Recalls For Megadyne And Draeger, Elixir Stent Trial Moves Ahead
This week, companies including MedRhythms, Allergan and Urotronic announced FDA clearances; Quest and Envision launched a prostate cancer test; and the FDA designated two recalls as class I.
Keeping Track: Parsaclisib, Kymriah Applications Target Non-Hodgkin Lymphomas; AbbVie Gets New Use For Old Ophthalmic
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Cassava’s claims that its drug reversed cognitive decline in Alzheimer’s patients are seen as "too good to be true" by skeptics. A statement by former lab services partner Quanterix has further undermined investor confidence.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
- Digital Health
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- UmanDiagnostics AB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.